Key facts
- Ena Respiratory’s last known valuation is $32.4M (Jun 2021).
- It has raised $68.1M; the latest was Later Stage VC ($22.4M) in Oct 2025.
- Notable investors include United States Department of War, Gates Foundation, Hostplus Superannuation Fund, Brandon Capital, AustralianSuper — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Ena Respiratory
- ·The full record, as it builds
Funding rounds
No funding rounds for Ena Respiratory are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ena Respiratory
Developer of immunomodulators designed to prevent respiratory viral infections. The company's products allow for topical delivery to the airways in order to target the primary site and activate the innate immune system in the respiratory tract to prevent viral and bacterial dissemination to the lungs, enabling patients with pre-existing lung disease to stay safe from further critical complications.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2014
- Employees
- 8
- Website
- enarespiratory.com/
- Ownership
- Privately Held (backing)
Ena Respiratory doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ena Respiratory shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ena Respiratory in its N-PORT filings yet. We sweep new filings monthly.